RACHAEL CROSBY: Open Payments
NPI 1396936423 · WICHITA, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$580 in 27 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $56 · 2025 $580
Food & beverage: $580
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $124 |
| Novo Nordisk Inc | 5 | $94 |
| Amgen Inc. | 5 | $88 |
| Janssen Biotech, Inc. | 4 | $67 |
| Novartis Pharmaceuticals Corporation | 3 | $46 |
| Aimmune Therapeutics, Inc. | 2 | $46 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $29 |
| Alexion Pharmaceuticals, Inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $16 |
| Boston Scientific Corporation | 1 | $16 |
Products named: Kerendia, Wegovy, OTEZLA, TREMFYA, LEQVIO, ZENPEP, XIFAXAN, STRENSIQ.
Industry payments across KS — which companies pay providers there.
